Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alopecia | 3 | 2018 | 126 | 1.200 |
Why?
|
| Breast Neoplasms | 16 | 2023 | 15694 | 0.760 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 95 | 0.610 |
Why?
|
| Scalp | 1 | 2017 | 156 | 0.530 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 170 | 0.530 |
Why?
|
| RANK Ligand | 1 | 2012 | 119 | 0.400 |
Why?
|
| Plasmacytoma | 1 | 2011 | 111 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 15862 | 0.370 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2022 | 1215 | 0.330 |
Why?
|
| Quality of Life | 3 | 2018 | 4532 | 0.310 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 674 | 0.270 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 1216 | 0.270 |
Why?
|
| Receptor, ErbB-2 | 5 | 2023 | 2518 | 0.250 |
Why?
|
| Quinolines | 3 | 2022 | 383 | 0.210 |
Why?
|
| Proteogenomics | 1 | 2022 | 87 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 521 | 0.200 |
Why?
|
| Estrogen Antagonists | 1 | 2022 | 184 | 0.200 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 1058 | 0.200 |
Why?
|
| Adenomyoepithelioma | 1 | 2019 | 9 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 2138 | 0.180 |
Why?
|
| Cholecalciferol | 1 | 2019 | 46 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 2576 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 4367 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 436 | 0.170 |
Why?
|
| Arthralgia | 1 | 2019 | 89 | 0.160 |
Why?
|
| Hair Diseases | 1 | 2018 | 43 | 0.160 |
Why?
|
| Cryotherapy | 1 | 2018 | 67 | 0.160 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2018 | 45 | 0.160 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 79 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14289 | 0.150 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 214 | 0.150 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 85 | 0.150 |
Why?
|
| Female | 21 | 2023 | 141928 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 305 | 0.150 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 183 | 0.140 |
Why?
|
| Anthracyclines | 1 | 2017 | 331 | 0.130 |
Why?
|
| Neoplasms | 2 | 2018 | 15193 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2017 | 255 | 0.130 |
Why?
|
| Humans | 24 | 2023 | 261506 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 878 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 840 | 0.120 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 679 | 0.120 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.110 |
Why?
|
| Jejunal Neoplasms | 1 | 2012 | 34 | 0.110 |
Why?
|
| Jejunal Diseases | 1 | 2012 | 25 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 4849 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2011 | 829 | 0.100 |
Why?
|
| Denosumab | 1 | 2012 | 68 | 0.100 |
Why?
|
| Intussusception | 1 | 2012 | 52 | 0.100 |
Why?
|
| Phyllodes Tumor | 1 | 2012 | 62 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2015 | 1996 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2018 | 1824 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2015 | 554 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 607 | 0.090 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 10331 | 0.090 |
Why?
|
| Risk Factors | 3 | 2021 | 17523 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1303 | 0.090 |
Why?
|
| Trastuzumab | 2 | 2023 | 696 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2021 | 6869 | 0.080 |
Why?
|
| Aged | 8 | 2022 | 70117 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 4975 | 0.080 |
Why?
|
| Middle Aged | 11 | 2019 | 86204 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 690 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 3251 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 184 | 0.070 |
Why?
|
| Skin | 1 | 2011 | 1259 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2022 | 2231 | 0.070 |
Why?
|
| Mastectomy, Segmental | 2 | 2022 | 1026 | 0.070 |
Why?
|
| Adult | 7 | 2019 | 77950 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2011 | 2358 | 0.060 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 62 | 0.060 |
Why?
|
| Breast | 2 | 2019 | 1344 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2022 | 116 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2023 | 32848 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2022 | 145 | 0.050 |
Why?
|
| Oxazepines | 1 | 2019 | 2 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 823 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 89 | 0.040 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 112 | 0.040 |
Why?
|
| Pimozide | 1 | 2018 | 9 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 2018 | 15 | 0.040 |
Why?
|
| Quinazolines | 1 | 2023 | 923 | 0.040 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 38 | 0.040 |
Why?
|
| Capecitabine | 1 | 2019 | 388 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 875 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 62 | 0.040 |
Why?
|
| Craniotomy | 1 | 2019 | 304 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5112 | 0.040 |
Why?
|
| Prognosis | 3 | 2022 | 21713 | 0.040 |
Why?
|
| Survival Rate | 2 | 2019 | 12221 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 7551 | 0.030 |
Why?
|
| Proteomics | 1 | 2022 | 1380 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 906 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 60 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 558 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1832 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 508 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 999 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 414 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 13658 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 452 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 258 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3472 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 29902 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2803 | 0.030 |
Why?
|
| Apoptosis | 2 | 2018 | 7591 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 2588 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2086 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1959 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 59536 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 6682 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3890 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5047 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3981 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4320 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4078 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 3443 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 9244 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 4113 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5159 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2018 | 3341 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 4757 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 14889 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 4844 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 21445 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 11965 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 34495 | 0.010 |
Why?
|
| Male | 1 | 2008 | 123000 | 0.000 |
Why?
|